Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 129 of 129 entries
Sorted by: Best Match Show Resources per page
Tailoring precision immunotherapy: coming to a clinic soon?.

ESMO open

Han S, Shuen WH, Wang WW, Nazim E, Toh HC.
PMID: 33558033
ESMO Open. 2020;5:e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30.

Cell-based and antibody-based cancer immunotherapies have been widely tested across increasing numbers of cancers with an unprecedented number of successful practice-changing immunotherapy clinical trials, achieving significant survival outcomes and, characteristically, some very long-term survivors. Still, a sizeable proportion of...

Cite
Han S, Shuen WH, Wang WW, et al. Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open. 2020;5:e000631doi: 10.1136/esmoopen-2019-000631.
Han, S., Shuen, W. H., Wang, W. W., Nazim, E., & Toh, H. C. (2020). Tailoring precision immunotherapy: coming to a clinic soon?. ESMO open, 5e000631. https://doi.org/10.1136/esmoopen-2019-000631
Han, Shuting, et al. "Tailoring precision immunotherapy: coming to a clinic soon?." ESMO open vol. 5 (2020): e000631. doi: https://doi.org/10.1136/esmoopen-2019-000631
Han S, Shuen WH, Wang WW, Nazim E, Toh HC. Tailoring precision immunotherapy: coming to a clinic soon?. ESMO Open. 2020;5:e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30. PMID: 33558033; PMCID: PMC7046383.
Copy Download .nbib Format: NLM
[Ⅴ. Novel Immunotherapies Targeting Tumor-Associated Macrophages].

Gan to kagaku ryoho. Cancer & chemotherapy

Takahashi H.
PMID: 34267027
Gan To Kagaku Ryoho. 2021 Jul;48(7):907-909.

No abstract available.

Cite
Takahashi H. [Ⅴ. Novel Immunotherapies Targeting Tumor-Associated Macrophages]. Gan To Kagaku Ryoho. 2021;48(7):907-909
Takahashi, H. (2021). [Ⅴ. Novel Immunotherapies Targeting Tumor-Associated Macrophages]. Gan to kagaku ryoho. Cancer & chemotherapy, 48(7), 907-909.
Takahashi, Hideyuki. "[Ⅴ. Novel Immunotherapies Targeting Tumor-Associated Macrophages]." Gan to kagaku ryoho. Cancer & chemotherapy vol. 48,7 (2021): 907-909.
Takahashi H. [Ⅴ. Novel Immunotherapies Targeting Tumor-Associated Macrophages]. Gan To Kagaku Ryoho. 2021 Jul;48(7):907-909. Japanese. PMID: 34267027.
Copy Download .nbib Format: NLM
Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines.

Advanced healthcare materials

Cheng Y, Song S, Wu P, Lyu B, Qin M, Sun Y, Sun A, Mu L, Xu F, Zhang L, Wang J, Zhang Q.
PMID: 34292673
Adv Healthc Mater. 2021 Sep;10(18):e2100590. doi: 10.1002/adhm.202100590. Epub 2021 Jul 22.

As an important part of tumor microenvironment, tumor associated macrophages (TAMs) play a vital role in the occurrence, development, invasion, and metastasis of many malignant tumors and can significantly promote the formation of tumor blood vessels and lymphatic vessels,...

Cite
Cheng Y, Song S, Wu P, et al. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines. Adv Healthc Mater. 2021;10(18):e2100590doi: 10.1002/adhm.202100590.
Cheng, Y., Song, S., Wu, P., Lyu, B., Qin, M., Sun, Y., Sun, A., Mu, L., Xu, F., Zhang, L., Wang, J., & Zhang, Q. (2021). Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines. Advanced healthcare materials, 10(18), e2100590. https://doi.org/10.1002/adhm.202100590
Cheng, Yuxi, et al. "Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines." Advanced healthcare materials vol. 10,18 (2021): e2100590. doi: https://doi.org/10.1002/adhm.202100590
Cheng Y, Song S, Wu P, Lyu B, Qin M, Sun Y, Sun A, Mu L, Xu F, Zhang L, Wang J, Zhang Q. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines. Adv Healthc Mater. 2021 Sep;10(18):e2100590. doi: 10.1002/adhm.202100590. Epub 2021 Jul 22. PMID: 34292673.
Copy Download .nbib Format: NLM
Immunotherapies targeting stimulatory pathways and beyond.

Journal of hematology & oncology

Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y.
PMID: 33980266
J Hematol Oncol. 2021 May 12;14(1):78. doi: 10.1186/s13045-021-01085-3.

Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti-CTLA-4 and anti-PD-1/PD-L1 were developed to overcome these immunosuppressive effects. These agents have demonstrated...

Cite
Marin-Acevedo JA, Kimbrough EO, Manochakian R, et al. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021;14(1):78doi: 10.1186/s13045-021-01085-3.
Marin-Acevedo, J. A., Kimbrough, E. O., Manochakian, R., Zhao, Y., & Lou, Y. (2021). Immunotherapies targeting stimulatory pathways and beyond. Journal of hematology & oncology, 14(1), 78. https://doi.org/10.1186/s13045-021-01085-3
Marin-Acevedo, Julian A, et al. "Immunotherapies targeting stimulatory pathways and beyond." Journal of hematology & oncology vol. 14,1 (2021): 78. doi: https://doi.org/10.1186/s13045-021-01085-3
Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021 May 12;14(1):78. doi: 10.1186/s13045-021-01085-3. PMID: 33980266; PMCID: PMC8117548.
Copy Download .nbib Format: NLM
Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment.

Seminars in immunology

Zou W.
PMID: 33308923
Semin Immunol. 2020 Jun;49:101421. doi: 10.1016/j.smim.2020.101421. Epub 2020 Dec 09.

No abstract available.

Cite
Zou W. Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment. Semin Immunol. 2020;49:101421doi: 10.1016/j.smim.2020.101421.
Zou, W. (2020). Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment. Seminars in immunology, 49101421. https://doi.org/10.1016/j.smim.2020.101421
Zou, Weiping. "Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment." Seminars in immunology vol. 49 (2020): 101421. doi: https://doi.org/10.1016/j.smim.2020.101421
Zou W. Introduction to the special issue-Barriers and opportunities to cancer immunotherapy in the tumor immune microenvironment. Semin Immunol. 2020 Jun;49:101421. doi: 10.1016/j.smim.2020.101421. Epub 2020 Dec 09. PMID: 33308923.
Copy Download .nbib Format: NLM
Combinatorial therapy in tumor microenvironment: Where do we stand?.

Biochimica et biophysica acta. Reviews on cancer

Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P.
PMID: 34224836
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188585. doi: 10.1016/j.bbcan.2021.188585. Epub 2021 Jul 02.

The tumor microenvironment plays a pivotal role in tumor initiation and progression by creating a dynamic interaction with cancer cells. The tumor microenvironment consists of various cellular components, including endothelial cells, fibroblasts, pericytes, adipocytes, immune cells, cancer stem cells...

Cite
Kumari S, Advani D, Sharma S, et al. Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188585doi: 10.1016/j.bbcan.2021.188585.
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021). Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochimica et biophysica acta. Reviews on cancer, 1876(2), 188585. https://doi.org/10.1016/j.bbcan.2021.188585
Kumari, Smita, et al. "Combinatorial therapy in tumor microenvironment: Where do we stand?." Biochimica et biophysica acta. Reviews on cancer vol. 1876,2 (2021): 188585. doi: https://doi.org/10.1016/j.bbcan.2021.188585
Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P. Combinatorial therapy in tumor microenvironment: Where do we stand?. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188585. doi: 10.1016/j.bbcan.2021.188585. Epub 2021 Jul 02. PMID: 34224836.
Copy Download .nbib Format: NLM
[Roles of highly expressed bone-specific genes in bone metastatic prostate cancer PC3 cells: Advances in studies].

Zhonghua nan ke xue = National journal of andrology

Zhou SY, Wang D, Shao JC, You YD.
PMID: 34914272
Zhonghua Nan Ke Xue. 2021 Oct 20;27(10):927-933.

Prostate cancer (PCa) is a maligmancy with high morbidity and mortality. Bone metastasis is the main cause of short survival time and difficulties in the treatment and prevention of PCa. Previous findings of our team showed 155 bone-specific genes...

Cite
Zhou SY, Wang D, Shao JC, et al. [Roles of highly expressed bone-specific genes in bone metastatic prostate cancer PC3 cells: Advances in studies]. Zhonghua Nan Ke Xue. 2021;27(10):927-933
Zhou, S. Y., Wang, D., Shao, J. C., & You, Y. D. (2021). [Roles of highly expressed bone-specific genes in bone metastatic prostate cancer PC3 cells: Advances in studies]. Zhonghua nan ke xue = National journal of andrology, 27(10), 927-933.
Zhou, Shi-Yi, et al. "[Roles of highly expressed bone-specific genes in bone metastatic prostate cancer PC3 cells: Advances in studies]." Zhonghua nan ke xue = National journal of andrology vol. 27,10 (2021): 927-933.
Zhou SY, Wang D, Shao JC, You YD. [Roles of highly expressed bone-specific genes in bone metastatic prostate cancer PC3 cells: Advances in studies]. Zhonghua Nan Ke Xue. 2021 Oct 20;27(10):927-933. Chinese. PMID: 34914272.
Copy Download .nbib Format: NLM
Mathematical simulation and prediction of tumor volume using RBF artificial neural network at different circumstances in the tumor microenvironment.

Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine

Akbarpour Ghazani M, Saghafian M, Jalali P, Soltani M.
PMID: 34247529
Proc Inst Mech Eng H. 2021 Nov;235(11):1335-1355. doi: 10.1177/09544119211028380. Epub 2021 Jul 10.

Uncontrolled proliferation of cells in a tissue caused by genetic mutations inside a cell is referred to as a tumor. A tumor which grows rapidly encounters a barrier when it grows to a certain size in presence of preexisting...

Cite
Akbarpour Ghazani M, Saghafian M, Jalali P, et al. Mathematical simulation and prediction of tumor volume using RBF artificial neural network at different circumstances in the tumor microenvironment. Proc Inst Mech Eng H. 2021;235(11):1335-1355doi: 10.1177/09544119211028380.
Akbarpour Ghazani, M., Saghafian, M., Jalali, P., & Soltani, M. (2021). Mathematical simulation and prediction of tumor volume using RBF artificial neural network at different circumstances in the tumor microenvironment. Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine, 235(11), 1335-1355. https://doi.org/10.1177/09544119211028380
Akbarpour Ghazani, Mehran, et al. "Mathematical simulation and prediction of tumor volume using RBF artificial neural network at different circumstances in the tumor microenvironment." Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine vol. 235,11 (2021): 1335-1355. doi: https://doi.org/10.1177/09544119211028380
Akbarpour Ghazani M, Saghafian M, Jalali P, Soltani M. Mathematical simulation and prediction of tumor volume using RBF artificial neural network at different circumstances in the tumor microenvironment. Proc Inst Mech Eng H. 2021 Nov;235(11):1335-1355. doi: 10.1177/09544119211028380. Epub 2021 Jul 10. PMID: 34247529; PMCID: PMC8573697.
Copy Download .nbib Format: NLM
M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.

Annals of medicine

JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C.
PMID: 34032524
Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396.

BACKGROUND: Prostate cancer (PCa) is poor response to the immunotherapy for its high heterogeneity of immune microenvironment. In this study, we aim to introduce a new immune subtype for PCa involving M2 tumour associated macrophages METHODS: Three hundred and...

Cite
JiaWei Z, ChunXia D, CunDong L, et al. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021;53(1):730-740doi: 10.1080/07853890.2021.1924396.
JiaWei, Z., ChunXia, D., CunDong, L., Yang, L., JianKun, Y., HaiFeng, D., Cheng, Y., ZhiPeng, H., HongYi, W., DeYing, L., ZhiJian, L., Xiao, X., QiZhao, Z., KangYi, X., WenBing, G., Ming, X., JunHao, Z., JiMing, B., ShanChao, Z., & MingKun, C. (2021). M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Annals of medicine, 53(1), 730-740. https://doi.org/10.1080/07853890.2021.1924396
JiaWei, Zhou, et al. "M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer." Annals of medicine vol. 53,1 (2021): 730-740. doi: https://doi.org/10.1080/07853890.2021.1924396
JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396. PMID: 34032524; PMCID: PMC8158194.
Copy Download .nbib Format: NLM
Showing 121 to 129 of 129 entries